<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9977">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01973205</url>
  </required_header>
  <id_info>
    <org_study_id>863-P-303</org_study_id>
    <nct_id>NCT01973205</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin
      versus placebo in the acute treatment of migraine
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent of subjects who are pain free at the 2-hour assessment</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects who are pain free at the 2-hour assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects who are nausea free at the 2-hour assessment</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects who are nausea free at the 2-hour assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who are free of photophobia at the 2-hour assessment.</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects who are free of photophobia at the 2-hour assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of subjects who are free of phonophobia at the 2-hour assessment.</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects who are free of phonophobia at the 2-hour assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acetaminophen 250 mg and aspirin 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen 250 mg and Aspirin 250 mg</intervention_name>
    <description>2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg</description>
    <arm_group_label>Acetaminophen 250 mg and aspirin 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or female aged 18 years and over.

          2. International Headache Society (IHS) diagnosis of migraine without aura or typical
             aura with migraine headache.

          3. History of experiencing at least 1, but not more than 8, acute migraine attacks
             monthly during the previous year.

          4. History of at least moderate migraine pain intensity, if left untreated.

          5. History of frequently or always experiencing nausea with the migraine attack.

        Exclusion criteria:

        Subjects eligible for inclusion in this study must not fulfill any of the following
        criteria:

          1. Headache symptoms which may be due to or aggravated by:

               -  Recent (within 6 months) head or neck trauma (e.g., whiplash)

               -  Head or neck pain secondary to an orthopedic abnormality

               -  Cluster headache

               -  Specific migraine variants (e.g., basilar-type artery migraine, opthalmoplegic
                  migraine, hemiplegic migraine, migraine aura without headache)

               -  Other serious, non-migraine causes of headache (e.g., increased intracranial
                  pressure, intracranial bleeding, meningitis, malignancy)

               -  Non-serious, non-migraine causes of headache (e.g., cold, flu, hangover)

          2. History of vomiting during more than 20% of migraine attacks.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Project Lead</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Consumer Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Clinical Project Leader</last_name>
    <phone>973-503-7812</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>October 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>aspirin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
